The January/February issue of NeuroPerspective has been released. It provides a comprehensive review of 2018, and a full appraisal of what to anticipate in 2019. 130 companies have capsule summaries of current activities and coming events, including AbbVie, Acorda, Adamas, Alkahest, Alkermes, Allergan, Biogen, Biohaven, Blackthorn, Denali, JNJ, Lilly, Lundbeck, Lysosomal Therapeutics, Marinus, Minerva, Neurocrine Biosciences, Novartis, Ovid, Perception, Pfizer, Roche, SAGE, Sunovion, Teva, Voyager Therapeutics, Wave Life Sciences, Xenon, Yumanity, Zogenix, and one hundred more.
Highlights and Lowlights from 2018 are assessed, with particular consideration of 2018’s record inflow of financial resources from both investors and pharma partners; Roche/Ionis‘s preliminary data in Huntington’s; the anticipated advent of SAGE‘s Zulresso, as well as the status of potential competition from Marinus in Post-Partum Depression; Biogen‘s first foray into Psychiatry; the FDA’s support for trials of MDMA and psilocybin in a number of psychiatric disorders; the ambiguous impact of JNJ‘s esketamine as a treatment adjunct; and the disappointment of BioAxone‘s Cethrin in Spinal Cord Injury. For the first time in a couple years, NP has named recipients of our awards for Best and Worst CEO.
This issue also includes a guest article from Joel Sanders PhD (Cello Health) reviewing the expanding range of gene therapy programs in neurodegeneration, including Novartis/AveXis, Biogen/Ionis, PTC/Agilism AbbVie/Voyager, Takeda/WAVE, and many more. The Jan/Feb NP also provides a succinct review assessing the rise of digital technologies in clinical trials and treatment, via companies like MindStrong, AiCure, TrialSpark, Science 37, Pear Therapeutics, Click Therapeutics. HeadSpace, and DThera.
The Company Spotlight covers Syndesi Therapeutics, developing procognitive compounds spun out by UCB Pharma.